Clinical Trials

MIRT Ireland announce a new joint US-Ireland clinic trial-the “RVD-SC Trial”

Date Posted: 4th September 2013

MIRT Ireland are delighted to announce a new joint US-Ireland clinic trial-the “RVD-SC Trial” combining our best available drugs for Multiple Myeloma patients. Dr O Gorman in Ireland/Europe and Prof Paul Richardson in the US are the co-Principal Investigators. The trial will be run by the Irish Clinical Oncology Research Group in Ireland and the […]

Category Clinical Trials, MIRT News |

Denosumab

Date Posted: 24th September 2012

Open November ’12 Title: A randomised double-blind study of Denosumab V’s Zoledronic Acid (Zometa) in the treatment of bone disease in patients with Newly Diagnosed Multiple Myeloma. Population: Patients with newly diagnosed MM who are for first line treatment and who have never received previous Intravenous biphosphonate treatment. Resource Links http://clinicaltrials.gov/ct2/show/NCT01345019 http://www.myeloma.org.uk/patient-services/faqs/new-myeloma-drugs-and-clinical-studies/

Category Clinical Trials |

Perifosine

Date Posted: 24th September 2012

Open November ’12 Title: A Phase 3 randomized study to assess the efficacy and safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients Previously Treated with Bortezomib. Population: Patients who received 1 – 4 prior treatments and are not refractory to Bortezomib (No disease progression within 60 days of […]

Category Clinical Trials |

GSK OMB- OFATUMUMAB

Date Posted: 20th September 2012

Title: A phase 3 randomised study of Ofatumumab V’s Physicians choice in treatment of bulky Fludarabine refractory Chronic Lymphocytic Leukaemia (CLL).. Population: Refractory to Fludarabine: Either no response to at least 2 cycles OR at least a Partial Response after 2 cycles lasting less than 6 months. Must have one Lymph Node >5cm. Resource Links […]

Category Clinical Trials |

ELOQUENT 2

Date Posted: 20th September 2012

Title: A phase 3 randomised trial of Lenalidomide and Dexamethasone with or without Elotuzumab in Relapsed or Refractory Multiple Myeloma. Population: Patients who have had 1-3 prior lines of treatment. May have had bortezomib or thalidomide. Can only have had Lenalidomide if: – Achieved at least Partial response – Had max 9 cycles – Are […]

Category Clinical Trials |

ELOQUENT

Date Posted: 20th September 2012

Title: A phase 3 randomised trial of Lenalidomide and Dexamethasone with or without Elotuzumab in previously untreated Multiple Myeloma. Population: Patients not eligible for high dose Treatment & Stem cell transplant due to age (>65) or co-morbities. Resource Links: http://clinicaltrials.gov/ct2/show/NCT01335399 https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022445-20/IE

Category Clinical Trials |
« Back